Skip to main content
NCBI home page
Protein & Cell logoLink to Protein & Cell
. 2012 Mar 23;3(3):182–197. doi: 10.1007/s13238-012-2020-y

Polo-like kinase 1, on the rise from cell cycle regulation to prostate cancer development

Jijing Luo 1, Xiaoqi Liu 1,✉
PMCID: PMC4875424  PMID: 22447658

Abstract

Polo-like kinase 1 (Plk1), a well-characterized member of serine/threonine kinases Plk family, has been shown to play pivotal roles in mitosis and cytokinesis in eukaryotic cells. Recent studies suggest that Plk1 not only controls the process of mitosis and cytokinesis, but also, going beyond those previously described functions, plays critical roles in DNA replication and Pten null prostate cancer initiation. In this review, we briefly summarize the functions of Plk1 in mitosis and cytokinesis, and then mainly focus on newly discovered functions of Plk1 in DNA replication and in Pten-null prostate cancer initiation. Furthermore, we briefly introduce the architectures of human and mouse prostate glands and the possible roles of Plk1 in human prostate cancer development. And finally, the newly chemotherapeutic development of small-molecule Plk1 inhibitors to target Plk1 in cancer treatment and their translational studies are also briefly reviewed.

Keywords: polo-like kinase 1, cell cycle regulation, Orc2, DNA replication, early embryonic development, prostate cancer, Pten, cancer initiation and progression, translational studies

References

  1. Ahmad N. Polo-like kinase (Plk) 1: a novel target for the treatment of prostate cancer. FASEB J. 2004;18:5–7. doi: 10.1096/fj.03-0848hyp. [DOI] [PubMed] [Google Scholar]
  2. Ahonen L.J., Kallio M.J., Daum J.R., Bolton M., Manke I.A., Yaffe M.B., Stukenberg P.T., Gorbsky G.J. Polo-like kinase 1 creates the tension-sensing 3F3/2 phosphoepitope and modulates the association of spindle-checkpoint proteins at kinetochores. Curr Biol. 2005;15:1078–1089. doi: 10.1016/j.cub.2005.05.026. [DOI] [PubMed] [Google Scholar]
  3. American Cancer Society. Cancer facts & figures 2009. Atlanta, GA: American Cancer Society; 2009. [Google Scholar]
  4. Andrysik Z., Bernstein W.Z., Deng L., Myer D.L., Li Y.-Q., Tischfield J.A., Stambrook P.J., Bahassi M. The novel mouse Polo-like kinase 5 responds to DNA damage and localizes in the nucleolus. Nucleic Acids Res. 2010;38:2931–2943. doi: 10.1093/nar/gkq011. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Archambault V., Glover D.M. Polo-like kinases: conservation and divergence in their functions and regulation. Nat Rev Mol Cell Biol. 2009;10:265–275. doi: 10.1038/nrm2653. [DOI] [PubMed] [Google Scholar]
  6. Bahassi el M. Polo-like kinases and DNA damage checkpoint: beyond the traditional mitotic functions. Exp Biol Med. 2011;236:648–657. doi: 10.1258/ebm.2011.011011. [DOI] [PubMed] [Google Scholar]
  7. Barr F.A., Gruneberg U. Cytokinesis: placing and making the final cut. Cell. 2007;131:847–860. doi: 10.1016/j.cell.2007.11.011. [DOI] [PubMed] [Google Scholar]
  8. Barr F.A., Silljé H.H., Nigg E.A. Polo-like kinases and the orchestration of cell division. Nat Rev Mol Cell Biol. 2004;5:429–440. doi: 10.1038/nrm1401. [DOI] [PubMed] [Google Scholar]
  9. Bartsch G., Frick J., Rüegg I., Bucher M., Holliger O., Oberholzer M., Rohr H.P. Electron microscopic stereological analysis of the normal human prostate and of benign prostatic hyperplasia. J Urol. 1979;122:481–486. doi: 10.1016/s0022-5347(17)56475-7. [DOI] [PubMed] [Google Scholar]
  10. Bell S.P., Dutta A. DNA replication in eukaryotic cells. Annu Rev Biochem. 2002;71:333–374. doi: 10.1146/annurev.biochem.71.110601.135425. [DOI] [PubMed] [Google Scholar]
  11. Bell S.P., Stillman B. ATP-dependent recognition of eukaryotic origins of DNA replication by a multiprotein complex. Nature. 1992;357:128–134. doi: 10.1038/357128a0. [DOI] [PubMed] [Google Scholar]
  12. Berquin I.M., Min Y., Wu R., Wu H., Chen Y.Q. Expression signature of the mouse prostate. J Biol Chem. 2005;280:36442–36451. doi: 10.1074/jbc.M504945200. [DOI] [PubMed] [Google Scholar]
  13. Blow J.J., Dutta A. Preventing re-replication of chromosomal DNA. Nat Rev Mol Cell Biol. 2005;6:476–486. doi: 10.1038/nrm1663. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Bonkhoff H., Wernert N., Dhom G., Remberger K. Basement membranes in fetal, adult normal, hyperplastic and neoplastic human prostate. Virchows Arch A Pathol Anat Histopathol. 1991;418:375–381. doi: 10.1007/BF01605922. [DOI] [PubMed] [Google Scholar]
  15. Bonkhoff H., Wernert N., Dhom G., Remberger K. Distribution of basement membranes in primary and metastatic carcinomas of the prostate. Hum Pathol. 1992;23:934–93. doi: 10.1016/0046-8177(92)90408-u. [DOI] [PubMed] [Google Scholar]
  16. Brawer M.K., Peehl D.M., Stamey T.A., Bostwick D.G. Keratin immunoreactivity in the benign and neoplastic human prostate. Cancer Res. 1985;45:3663–3667. [PubMed] [Google Scholar]
  17. Burkard M.E., Maciejowski J., Rodriguez-Bravo V., Repka M., Lowery D.M., Clauser K.R., Zhang C., Shokat K.M., Carr S.A., Yaffe M.B., et al. Plk1 self-organization and priming phosphorylation of HsCYK-4 at the spindle midzone regulate the onset of division in human cells. PLoS Biol. 2009;7:e1000111. doi: 10.1371/journal.pbio.1000111. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Carver B.S., Chapinski C., Wongvipat J., Hieronymus H., Chen Y., Chandarlapaty S., Arora V.K., Le C., Koutcher J., Scher H., et al. Reciprocal feedback regulation of PI3K and androgen receptor signaling in PTEN-deficient prostate cancer. Cancer Cell. 2011;19:575–586. doi: 10.1016/j.ccr.2011.04.008. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Casenghi M., Barr F.A., Nigg E.A. Phosphorylation of Nlp by Plk1 negatively regulates its dynein-dynactin-dependent targeting to the centrosome. J Cell Sci. 2005;118:5101–5108. doi: 10.1242/jcs.02622. [DOI] [PubMed] [Google Scholar]
  20. Casenghi M., Meraldi P., Weinhart U., Duncan P.I., Körner R., Nigg E.A. Polo-like kinase 1 regulates Nlp, a centrosome protein involved in microtubule nucleation. Dev Cell. 2003;5:113–125. doi: 10.1016/s1534-5807(03)00193-x. [DOI] [PubMed] [Google Scholar]
  21. Cheng K.-Y., Lowe E.D., Sinclair J., Nigg E.A., Johnson L.N. The crystal structure of the human polo-like kinase-1 polo box domain and its phospho-peptide complex. EMBO J. 2003;22:5757–5768. doi: 10.1093/emboj/cdg558. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Clay F.J., McEwen S.J., Bertoncello I., Wilks A.F., Dunn A.R. Identification and cloning of a protein kinase-encoding mouse gene, Plk, related to the polo gene of Drosophila. Proc Natl Acad Sci U S A. 1993;90:4882–4886. doi: 10.1073/pnas.90.11.4882. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Eckerdt F., Strebhardt K. Polo-like kinase 1: target and regulator of anaphase-promoting complex/cyclosome-dependent proteolysis. Cancer Res. 2006;66:6895–6898. doi: 10.1158/0008-5472.CAN-06-0358. [DOI] [PubMed] [Google Scholar]
  24. Eckerdt F., Yuan J., Strebhardt K. Polo-like kinases and oncogenesis. Oncogene. 2005;24:267–276. doi: 10.1038/sj.onc.1208273. [DOI] [PubMed] [Google Scholar]
  25. El Sheikh S.S., Romanska H.M., Abel P., Domin J., Lalani N. Predictive value of PTEN and AR coexpression of sustained responsiveness to hormonal therapy in prostate cancer—a pilot study. Neoplasia. 2008;10:949–953. doi: 10.1593/neo.08582. [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. Elia A.E., Cantley L.C., Yaffe M.B. Proteomic screen finds pSer/pThr-binding domain localizing Plk1 to mitotic substrates. Science. 2003;299:1228–1231. doi: 10.1126/science.1079079. [DOI] [PubMed] [Google Scholar]
  27. Elia A.E.H., Rellos P., Haire L.F., Chao J.W., Ivins F.J., Hoepker K., Mohammad D., Cantley L.C., Smerdon S.J., Yaffe M.B. The molecular basis for phosphodependent substrate targeting and regulation of Plks by the Polo-box domain. Cell. 2003;115:83–95. doi: 10.1016/s0092-8674(03)00725-6. [DOI] [PubMed] [Google Scholar]
  28. Elowe S., Hümmer S., Uldschmid A., Li X., Nigg E.A. Tension-sensitive Plk1 phosphorylation on BubR1 regulates the stability of kinetochore microtubule interactions. Genes Dev. 2007;21:2205–2219. doi: 10.1101/gad.436007. [DOI] [PMC free article] [PubMed] [Google Scholar]
  29. Foster C.S., Dodson A., Karavana V., Smith P.H., Ke Y. Prostatic stem cells. J Pathol. 2002;197:551–565. doi: 10.1002/path.1194. [DOI] [PubMed] [Google Scholar]
  30. Galgoczy D.J., Toczyski D.P. Checkpoint adaptation precedes spontaneous and damage-induced genomic instability in yeast. Mol Cell Biol. 2001;21:1710–1718. doi: 10.1128/MCB.21.5.1710-1718.2001. [DOI] [PMC free article] [PubMed] [Google Scholar]
  31. Gandhi, L., Chu, Q.S., Stephenson, J., et al. (2009). An open label phase II trial of the Plk1 inhibitor BI 2536, in patients with sensitive relapsed small cell lung cancer (SCLC). J Clin Oncol, 27. [abstract 8108]
  32. Gao H., Ouyang X., Banach-Petrosky W.A., Shen M.M., Abate-Shen C. Emergence of androgen independence at early stages of prostate cancer progression in Nkx3.1; Pten mice. Cancer Res. 2006;66:7929–7933. doi: 10.1158/0008-5472.CAN-06-1637. [DOI] [PubMed] [Google Scholar]
  33. Garland L.L., Taylor C., Pilkington D.L., Cohen J.L., Von Hoff D.D. A phase I pharmacokinetic study of HMN-214, a novel oral stilbene derivative with polo-like kinase-1-interacting properties, in patients with advanced solid tumors. Clin Cancer Res. 2006;12:5182–5189. doi: 10.1158/1078-0432.CCR-06-0214. [DOI] [PubMed] [Google Scholar]
  34. Giordano-Coltart J., Ying C.Y., Gautier J., Hurwitz J. Studies of the properties of human origin recognition complex and its Walker A motif mutants. Proc Natl Acad Sci U S A. 2005;102:69–74. doi: 10.1073/pnas.0408690102. [DOI] [PMC free article] [PubMed] [Google Scholar]
  35. Glover D.M., Hagan I.M., Tavares A.A.M. Polo-like kinases: a team that plays throughout mitosis. Genes Dev. 1998;12:3777–3787. doi: 10.1101/gad.12.24.3777. [DOI] [PubMed] [Google Scholar]
  36. Golsteyn R.M., Mundt K.E., Fry A.M., Nigg E.A. Cell cycle regulation of the activity and subcellular localization of Plk1, a human protein kinase implicated in mitotic spindle function. J Cell Biol. 1995;129:1617–1628. doi: 10.1083/jcb.129.6.1617. [DOI] [PMC free article] [PubMed] [Google Scholar]
  37. Golsteyn R.M., Schultz S.J., Bartek J., Ziemiecki A., Ried T., Nigg E.A. Cell cycle analysis and chromosomal localization of human Plk1, a putative homologue of the mitotic kinases Drosophila polo and Saccharomyces cerevisiae Cdc5. J Cell Sci. 1994;107:1509–1517. doi: 10.1242/jcs.107.6.1509. [DOI] [PubMed] [Google Scholar]
  38. Goto H., Kiyono T., Tomono Y., Kawajiri A., Urano T., Furukawa K., Nigg E.A., Inagaki M. Complex formation of Plk1 and INCENP required for metaphase-anaphase transition. Nat Cell Biol. 2006;8:180–187. doi: 10.1038/ncb1350. [DOI] [PubMed] [Google Scholar]
  39. Gray P.J., Jr, Bearss D.J., Han H., Nagle R., Tsao M.-S., Dean N., Von Hoff D.D. Identification of human polo-like kinase 1 as a potential therapeutic target in pancreatic cancer. Mol Cancer Ther. 2004;3:641–646. [PubMed] [Google Scholar]
  40. Guan R., Tapang P., Leverson J.D., Albert D., Giranda V.L., Luo Y. Small interfering RNA-mediated Polo-like kinase 1 depletion preferentially reduces the survival of p53-defective, oncogenic transformed cells and inhibits tumor growth in animals. Cancer Res. 2005;65:2698–2704. doi: 10.1158/0008-5472.CAN-04-2131. [DOI] [PubMed] [Google Scholar]
  41. Gumireddy K., Reddy M.V., Cosenza S.C., Boominathan R., Baker S.J., Papathi N., Jiang J., Holland J., Reddy E.P. ON01910, a non-ATP-competitive small molecule inhibitor of Plk1, is a potent anticancer agent. Cancer Cell. 2005;7:275–286. doi: 10.1016/j.ccr.2005.02.009. [DOI] [PubMed] [Google Scholar]
  42. Hanisch A., Wehner A., Nigg E.A., Silljé H.H. Different Plk1 functions show distinct dependencies on Polo-Box domain-mediated targeting. Mol Biol Cell. 2006;17:448–459. doi: 10.1091/mbc.E05-08-0801. [DOI] [PMC free article] [PubMed] [Google Scholar]
  43. Hansen D.V., Loktev A.V., Ban K.H., Jackson P.K. Plk1 regulates activation of the anaphase promoting complex by phosphorylating and triggering SCFbetaTrCP-dependent destruction of the APC Inhibitor Emi1. Mol Biol Cell. 2004;15:5623–5634. doi: 10.1091/mbc.E04-07-0598. [DOI] [PMC free article] [PubMed] [Google Scholar]
  44. Hudson D.L. Epithelial stem cells in human prostate growth and disease. Prostate Cancer Prostatic Dis. 2004;7:188–194. doi: 10.1038/sj.pcan.4500745. [DOI] [PubMed] [Google Scholar]
  45. Hudson J.W., Kozarova A., Cheung P., Macmillan J.C., Swallow C.J., Cross J.C., Dennis J.W. Late mitotic failure in mice lacking Sak, a polo-like kinase. Curr Biol. 2001;11:441–446. doi: 10.1016/s0960-9822(01)00117-8. [DOI] [PubMed] [Google Scholar]
  46. Iizuka M., Stillman B. Histone acetyltransferase HBO1 interacts with the ORC1 subunit of the human initiator protein. J Biol Chem. 1999;274:23027–23034. doi: 10.1074/jbc.274.33.23027. [DOI] [PubMed] [Google Scholar]
  47. Inoue D., Sagata N. The Polo-like kinase Plx1 interacts with and inhibits Myt1 after fertilization of Xenopus eggs. EMBO J. 2005;24:1057–1067. doi: 10.1038/sj.emboj.7600567. [DOI] [PMC free article] [PubMed] [Google Scholar]
  48. Ito Y., Miyoshi E., Sasaki N., Kakudo K., Yoshida H., Tomoda C., Uruno T., Takamura Y., Miya A., Kobayashi K., et al. Polo-like kinase 1 overexpression is an early event in the progression of papillary carcinoma. Br J Cancer. 2004;90:414–418. doi: 10.1038/sj.bjc.6601540. [DOI] [PMC free article] [PubMed] [Google Scholar]
  49. Jackman M., Lindon C., Nigg E.A., Pines J. Active cyclin B1-Cdk1 first appears on centrosomes in prophase. Nat Cell Biol. 2003;5:143–148. doi: 10.1038/ncb918. [DOI] [PubMed] [Google Scholar]
  50. Jeong K., Jeong J.Y., Lee H.O., Choi E., Lee H. Inhibition of Plk1 induces mitotic infidelity and embryonic growth defects in developing zebrafish embryos. Dev Biol. 2010;345:34–48. doi: 10.1016/j.ydbio.2010.06.004. [DOI] [PubMed] [Google Scholar]
  51. Jiao J., Wang S., Qiao R., Vivanco I., Watson P.A., Sawyers C.L., Wu H. Murine cell lines derived from Pten null prostate cancer show the critical role of PTEN in hormone refractory prostate cancer development. Cancer Res. 2007;67:6083–6091. doi: 10.1158/0008-5472.CAN-06-4202. [DOI] [PubMed] [Google Scholar]
  52. Jimeno A., Li J., Messersmith W.A., Laheru D., Rudek M.A., Maniar M., Hidalgo M., Baker S.D., Donehower R.C. Phase I study of ON 01910.Na, a novel modulator of the Polo-like kinase 1 pathway, in adult patients with solid tumors. J Clin Oncol. 2008;26:5504–5510. doi: 10.1200/JCO.2008.17.9788. [DOI] [PMC free article] [PubMed] [Google Scholar]
  53. Johnson E.F., Stewart K.D., Woods K.W., Giranda V.L., Luo Y. Pharmacological and functional comparison of the polo-like kinase family: insight into inhibitor and substrate specificity. Biochemistry. 2007;46:9551–9563. doi: 10.1021/bi7008745. [DOI] [PubMed] [Google Scholar]
  54. Kang Y.H., Park J.-E., Yu L.-R., Soung N.-K., Yun S.-M., Bang J.K., Seong Y.-S., Yu H., Garfield S., Veenstra T.D., et al. Self-regulated Plk1 recruitment to kinetochores by the Plk1-PBIP1 interaction is critical for proper chromosome segregation. Mol Cell. 2006;24:409–422. doi: 10.1016/j.molcel.2006.10.016. [DOI] [PubMed] [Google Scholar]
  55. Knecht R., Elez R., Oechler M., Solbach C., von Ilberg C., Strebhardt K. Prognostic significance of polo-like kinase (PLK) expression in squamous cell carcinomas of the head and neck. Cancer Res. 1999;59:2794–2797. [PubMed] [Google Scholar]
  56. Knecht R., Oberhauser C., Strebhardt K. PLK (polo-like kinase), a new prognostic marker for oropharyngeal carcinomas. Int J Cancer. 2000;89:535–536. [PubMed] [Google Scholar]
  57. Knudsen B.S., Vasioukhin V. Mechanisms of prostate cancer initiation and progression. Adv Cancer Res. 2010;109:1–50. doi: 10.1016/B978-0-12-380890-5.00001-6. [DOI] [PubMed] [Google Scholar]
  58. Kothe M., Kohls D., Low S., Coli R., Cheng A.C., Jacques S.L., Johnson T.L., Lewis C., Loh C., Nonomiya J., et al. Structure of the catalytic domain of human polo-like kinase 1. Biochemistry. 2007;46:5960–5971. doi: 10.1021/bi602474j. [DOI] [PubMed] [Google Scholar]
  59. Kothe M., Kohls D., Low S., Coli R., Rennie G.R., Feru F., Kuhn C., Ding Y.H. Selectivity-determining residues in Plk1. Chem Biol Drug Des. 2007;70:540–546. doi: 10.1111/j.1747-0285.2007.00594.x. [DOI] [PubMed] [Google Scholar]
  60. Kumagai A., Dunphy W.G. Purification and molecular cloning of Plx1, a Cdc25-regulatory kinase from Xenopus egg extracts. Science. 1996;273:1377–1380. doi: 10.1126/science.273.5280.1377. [DOI] [PubMed] [Google Scholar]
  61. Kumagai A., Dunphy W.G. Repeated phosphopeptide motifs in Claspin mediate the regulated binding of Chk1. Nat Cell Biol. 2003;5:161–165. doi: 10.1038/ncb921. [DOI] [PubMed] [Google Scholar]
  62. Lake R.J., Jelinek W.R. Cell cycle- and terminal differentiation-associated regulation of the mouse mRNA encoding a conserved mitotic protein kinase. Mol Cell Biol. 1993;13:7793–7801. doi: 10.1128/mcb.13.12.7793. [DOI] [PMC free article] [PubMed] [Google Scholar]
  63. Lane H.A., Nigg E.A. Antibody microinjection reveals an essential role for human polo-like kinase 1 (Plk1) in the functional maturation of mitotic centrosomes. J Cell Biol. 1996;135:1701–1713. doi: 10.1083/jcb.135.6.1701. [DOI] [PMC free article] [PubMed] [Google Scholar]
  64. Lee K.S., Park J.-E., Kang Y.H., Zimmerman W., Soung N.-K., Seong Y.-S., Kwak S.-J., Erikson R.L. Mechanisms of mammalian polo-like kinase 1 (Plk1) localization: self-versus non-self-priming. Cell Cycle. 2008;7:141–145. doi: 10.4161/cc.7.2.5272. [DOI] [PubMed] [Google Scholar]
  65. Lee K.S., Yuan Y.L., Kuriyama R., Erikson R.L. Plk is an M-phase-specific protein kinase and interacts with a kinesin-like protein, CHO1/MKLP-1. Mol Cell Biol. 1995;15:7143–7151. doi: 10.1128/mcb.15.12.7143. [DOI] [PMC free article] [PubMed] [Google Scholar]
  66. Lee S.E., Pellicioli A., Malkova A., Foiani M., Haber J.E. The Saccharomyces recombination protein Tid1p is required for adaptation from G2/M arrest induced by a double-strand break. Curr Biol. 2001;11:1053–1057. doi: 10.1016/s0960-9822(01)00296-2. [DOI] [PubMed] [Google Scholar]
  67. Lénárt P., Petronczki M., Steegmaier M., Di Fiore B., Lipp J.J., Hoffmann M., Rettig W.J., Kraut N., Peters J.-M. The small-molecule inhibitor BI 2536 reveals novel insights into mitotic roles of polo-like kinase 1. Curr Biol. 2007;17:304–315. doi: 10.1016/j.cub.2006.12.046. [DOI] [PubMed] [Google Scholar]
  68. Li H., Liu X.S., Yang X., Song B., Wang Y., Liu X. Polo-like kinase 1 phosphorylation of p150Glued facilitates nuclear envelope breakdown during prophase. Proc Natl Acad Sci U S A. 2010;107:14633–14638. doi: 10.1073/pnas.1006615107. [DOI] [PMC free article] [PubMed] [Google Scholar]
  69. Li H., Liu X.S., Yang X., Wang Y., Wang Y., Turner J.R., Liu X. Phosphorylation of CLIP-170 by Plk1 and CK2 promotes timely formation of kinetochore-microtubule attachments. EMBO J. 2010;29:2953–2965. doi: 10.1038/emboj.2010.174. [DOI] [PMC free article] [PubMed] [Google Scholar]
  70. Li H., Wang Y., Liu X. Plk1-dependent phosphorylation regulates functions of DNA topoisomerase IIalpha in cell cycle progression. J Biol Chem. 2008;283:6209–6221. doi: 10.1074/jbc.M709007200. [DOI] [PubMed] [Google Scholar]
  71. Liang C., Weinreich M., Stillman B. ORC and Cdc6p interact and determine the frequency of initiation of DNA replication in the genome. Cell. 1995;81:667–676. doi: 10.1016/0092-8674(95)90528-6. [DOI] [PubMed] [Google Scholar]
  72. Liu A.Y., True L.D., LaTray L., Nelson P.S., Ellis W.J., Vessella R.L., Lange P.H., Hood L., van den Engh G. Cell-cell interaction in prostate gene regulation and cytodifferentiation. Proc Natl Acad Sci U S A. 1997;94:10705–10710. doi: 10.1073/pnas.94.20.10705. [DOI] [PMC free article] [PubMed] [Google Scholar]
  73. Liu X., Erikson R.L. Polo-like kinase (Plk)1 depletion induces apoptosis in cancer cells. Proc Natl Acad Sci U S A. 2003;100:5789–5794. doi: 10.1073/pnas.1031523100. [DOI] [PMC free article] [PubMed] [Google Scholar]
  74. Liu X., Zhou T., Kuriyama R., Erikson R.L. Molecular interactions of Polo-like-kinase 1 with the mitotic kinesin-like pro tein CHO1/MKLP-1. J Cell Sci. 2004;117:3233–3246. doi: 10.1242/jcs.01173. [DOI] [PubMed] [Google Scholar]
  75. Liu X.S., Li H., Song B., Liu X. Polo-like kinase 1 phosphorylation of G2 and S-phase-expressed 1 protein is essential for p53 inactivation during G2 checkpoint recovery. EMBO Rep. 2010;11:626–632. doi: 10.1038/embor.2010.90. [DOI] [PMC free article] [PubMed] [Google Scholar]
  76. Liu X.S., Song B., Elzey B.D., Ratliff T.L., Konieczny S.F., Cheng L., Ahmad N., Liu X. Polo-like kinase 1 facilitates loss of Pten tumor suppressor-induced prostate cancer formation. J Biol Chem. 2011;286:35795–35800. doi: 10.1074/jbc.C111.269050. [DOI] [PMC free article] [PubMed] [Google Scholar]
  77. Liu X.S., Song B., Liu X. The substrates of Plk1, beyond the functions in mitosis. Protein Cell. 2010;1:999–1010. doi: 10.1007/s13238-010-0131-x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  78. Llamazares S., Moreira A., Tavares A., Girdham C., Spruce B.A., Gonzalez C., Karess R.E., Glover D.M., Sunkel C.E. polo encodes a protein kinase homolog required for mitosis in Drosophila. Genes Dev. 1991;5:2153–2165. doi: 10.1101/gad.5.12a.2153. [DOI] [PubMed] [Google Scholar]
  79. Lu L.Y., Wood J.L., Minter-Dykhouse K., Ye L., Saunders T.L., Yu X., Chen J. Polo-like kinase 1 is essential for early embryonic development and tumor suppression. Mol Cell Biol. 2008;28:6870–6876. doi: 10.1128/MCB.00392-08. [DOI] [PMC free article] [PubMed] [Google Scholar]
  80. Ma S., Charron J., Erikson R.L. Role of Plk2 (Snk) in mouse development and cell proliferation. Mol Cell Biol. 2003;23:6936–6943. doi: 10.1128/MCB.23.19.6936-6943.2003. [DOI] [PMC free article] [PubMed] [Google Scholar]
  81. Macmillan J.C., Hudson J.W., Bull S., Dennis J.W., Swallow C.J. Comparative expression of the mitotic regulators SAK and PLK in colorectal cancer. Ann Surg Oncol. 2001;8:729–740. doi: 10.1007/s10434-001-0729-6. [DOI] [PubMed] [Google Scholar]
  82. Manke I.A., Lowery D.M., Nguyen A., Yaffe M.B. BRCT repeats as phosphopeptide-binding modules involved in protein targeting. Science. 2003;302:636–639. doi: 10.1126/science.1088877. [DOI] [PubMed] [Google Scholar]
  83. Martin B.T., Strebhardt K. Polo-like kinase 1: target and regulator of transcriptional control. Cell Cycle. 2006;5:2881–2885. doi: 10.4161/cc.5.24.3538. [DOI] [PubMed] [Google Scholar]
  84. Masai H., Matsumoto S., You Z., Yoshizawa-Sugata N., Oda M. Eukaryotic chromosome DNA replication: where, when, and how? Annu Rev Biochem. 2010;79:89–130. doi: 10.1146/annurev.biochem.052308.103205. [DOI] [PubMed] [Google Scholar]
  85. McNeal J.E. Origin and development of carcinoma in the prostate. Cancer. 1969;23:24–34. doi: 10.1002/1097-0142(196901)23:1<24::aid-cncr2820230103>3.0.co;2-1. [DOI] [PubMed] [Google Scholar]
  86. McNeal J.E. The zonal anatomy of the prostate. Prostate. 1981;2:35–49. doi: 10.1002/pros.2990020105. [DOI] [PubMed] [Google Scholar]
  87. McNeal J.E. Normal histology of the prostate. Am J Surg Pathol. 1988;12:619–633. doi: 10.1097/00000478-198808000-00003. [DOI] [PubMed] [Google Scholar]
  88. Moshe Y., Boulaire J., Pagano M., Hershko A. Role of Polo-like kinase in the degradation of early mitotic inhibitor 1, a regulator of the anaphase promoting complex/cyclosome. Proc Natl Acad Sci U S A. 2004;101:7937–7942. doi: 10.1073/pnas.0402442101. [DOI] [PMC free article] [PubMed] [Google Scholar]
  89. Mross K., Frost A., Steinbild S., Hedbom S., Rentschler J., Kaiser R., Rouyrre N., Trommeshauser D., Hoesl C.E., Munzert G. Phase I dose escalation and pharmacokinetic study of BI 2536, a novel Polo-like kinase 1 inhibitor, in patients with advanced solid tumors. J Clin Oncol. 2008;26:5511–5517. doi: 10.1200/JCO.2008.16.1547. [DOI] [PubMed] [Google Scholar]
  90. Nagle R.B., Ahmann F.R., McDaniel K.M., Paquin M.L., Clark V.A., Celniker A. Cytokeratin characterization of human prostatic carcinoma and its derived cell lines. Cancer Res. 1987;47:281–286. [PubMed] [Google Scholar]
  91. Nakajima H., Toyoshima-Morimoto F., Taniguchi E., Nishida E. Identification of a consensus motif for Plk (Polo-like kinase) phosphorylation reveals Myt1 as a Plk1 substrate. J Biol Chem. 2003;278:25277–25280. doi: 10.1074/jbc.C300126200. [DOI] [PubMed] [Google Scholar]
  92. Neef R., Gruneberg U., Kopajtich R., Li X., Nigg E.A., Sillje H., Barr F.A. Choice of Plk1 docking partners during mitosis and cytokinesis is controlled by the activation state of Cdk1. Nat Cell Biol. 2007;9:436–444. doi: 10.1038/ncb1557. [DOI] [PubMed] [Google Scholar]
  93. Niiya F., Tatsumoto T., Lee K.S., Miki T. Phosphorylation of the cytokinesis regulator ECT2 at G2/M phase stimulates association of the mitotic kinase Plk1 and accumulation of GTP-bound RhoA. Oncogene. 2006;25:827–837. doi: 10.1038/sj.onc.1209124. [DOI] [PubMed] [Google Scholar]
  94. Nishimura Y., Yonemura S. Centralspindlin regulates ECT2 and RhoA accumulation at the equatorial cortex during cytokinesis. J Cell Sci. 2006;119:104–114. doi: 10.1242/jcs.02737. [DOI] [PubMed] [Google Scholar]
  95. Nishino M., Kurasawa Y., Evans R., Lin S.-H., Brinkley B.R., Yu-Lee L.Y. NudC is required for Plk1 targeting to the kinetochore and chromosome congression. Curr Biol. 2006;16:1414–1421. doi: 10.1016/j.cub.2006.05.052. [DOI] [PubMed] [Google Scholar]
  96. Olmos, D., Allred, A., Sharma, R., et al. (2009). Phase I first-in-human study of the polo-like kinase-1 selective inhibitor, GSK461364, in patients with advanced solid tumors. J Clin Oncol, 27. [abstract 3536]
  97. Oshimori N., Ohsugi M., Yamamoto T. The Plk1 target Kizuna stabilizes mitotic centrosomes to ensure spindle bipolarity. Nat Cell Biol. 2006;8:1095–1101. doi: 10.1038/ncb1474. [DOI] [PubMed] [Google Scholar]
  98. Pandha, H.S., Protheroe, A., Wylie, J., et al. (2008). An open label phase II trial of BI 2536, a novel Plk1 inhibitor, in patients with metastatic hormone refractory prostate cancer (HRPC). J Clin Oncol, 26 [abstract 14547]
  99. Park J.E., Soung N.K., Johmura Y., Kang Y.H., Liao C., Lee K.H., Park C.H., Nicklaus M.C., Lee K.S. Polo-box domain: a versatile mediator of polo-like kinase function. Cell Mol Life Sci. 2010;67:1957–1970. doi: 10.1007/s00018-010-0279-9. [DOI] [PMC free article] [PubMed] [Google Scholar]
  100. Patnaik A., Forero L., Goetz A., et al. HMN-214, a novel oral antimicrotubular agent and inhibitor of Polo-like- and cyclin-dependent kinases: Clinical, pharmacokinetic (PK) and pharmacodynamic (PD) relationships observed in a phase I trial of a daily x 5 schedule every 28 days. Proc Am Soc Clin Oncol. 2003;22:514. [Google Scholar]
  101. Pavicic-Kaltenbrunner V., Mishima M., Glotzer M. Cooperative assembly of CYK-4/MgcRacGAP and ZEN-4/MKLP1 to form the centralspindlin complex. Mol Biol Cell. 2007;18:4992–5003. doi: 10.1091/mbc.E07-05-0468. [DOI] [PMC free article] [PubMed] [Google Scholar]
  102. Peehl D.M. Primary cell cultures as models of prostate cancer development. Endocr Relat Cancer. 2005;12:19–47. doi: 10.1677/erc.1.00795. [DOI] [PubMed] [Google Scholar]
  103. Petronczki M., Lénárt P., Peters J.M. Polo on the Rise-from Mitotic Entry to Cytokinesis with Plk1. Dev Cell. 2008;14:646–659. doi: 10.1016/j.devcel.2008.04.014. [DOI] [PubMed] [Google Scholar]
  104. Qi W., Tang Z., Yu H. Phosphorylation- and polo-box-dependent binding of Plk1 to Bub1 is required for the kinetochore localization of Plk1. Mol Biol Cell. 2006;17:3705–3716. doi: 10.1091/mbc.E06-03-0240. [DOI] [PMC free article] [PubMed] [Google Scholar]
  105. Reagan-Shaw S., Ahmad N. Polo-like kinase (Plk) 1 as a target for prostate cancer management. IUBMB Life. 2005;57:677–682. doi: 10.1080/15216540500305910. [DOI] [PubMed] [Google Scholar]
  106. Reagan-Shaw S., Ahmad N. Silencing of polo-like kinase (Plk) 1 via siRNA causes induction of apoptosis and impairment of mitosis machinery in human prostate cancer cells: implications for the treatment of prostate cancer. The FASEB J. 2005;19:611–613. doi: 10.1096/fj.04-2910fje. [DOI] [PubMed] [Google Scholar]
  107. Reid A.H.M., Attard G., Ambroisine L., Fisher G., Kovacs G., Brewer D., Clark J., Flohr P., Edwards S., Berney D.M., the Transatlantic Prostate Group et al. Molecular charac terisation of ERG, ETV1 and PTEN gene loci identifies patients at low and high risk of death from prostate cancer. Br J Cancer. 2010;102:678–684. doi: 10.1038/sj.bjc.6605554. [DOI] [PMC free article] [PubMed] [Google Scholar]
  108. Reindl W., Strebhardt K., Berg T. A high-throughput assay based on fluorescence polarization for inhibitors of the polo-box domain of polo-like kinase 1. Anal Biochem. 2008;383:205–209. doi: 10.1016/j.ab.2008.08.014. [DOI] [PubMed] [Google Scholar]
  109. Reindl W., Yuan J., Krämer A., Strebhardt K., Berg T. Inhibition of polo-like kinase 1 by blocking polo-box domain-dependent protein-protein interactions. Chem Biol. 2008;15:459–466. doi: 10.1016/j.chembiol.2008.03.013. [DOI] [PubMed] [Google Scholar]
  110. Reindl W., Yuan J., Krämer A., Strebhardt K., Berg T. A pan-specific inhibitor of the polo-box domains of polo-like kinases arrests cancer cells in mitosis. Chembiochem. 2009;10:1145–1148. doi: 10.1002/cbic.200900059. [DOI] [PubMed] [Google Scholar]
  111. Rosasco-Nitcher S.E., Lan W., Khorasanizadeh S., Stukenberg P.T. Centromeric Aurora-B activation requires TD-60, microtubules, and substrate priming phosphorylation. Science. 2008;319:469–472. doi: 10.1126/science.1148980. [DOI] [PubMed] [Google Scholar]
  112. Santamaria A., Neef R., Eberspächer U., Eis K., Husemann M., Mumberg D., Prechtl S., Schulze V., Siemeister G., Wortmann L., et al. Use of the novel Plk1 inhibitor ZK-thiazolidinone to elucidate functions of Plk1 in early and late stages of mitosis. Mol Biol Cell. 2007;18:4024–4036. doi: 10.1091/mbc.E07-05-0517. [DOI] [PMC free article] [PubMed] [Google Scholar]
  113. Sebastian, M., Reck, M., Digel, W., et al. (2009). Impact of BI2536, a novel Plk1 inhibitor, on disease progression and quality of life parameters in patients with non-small cell lung cancer: results of a randomized phase II trial. Ann Oncol, 19. [abstract 295]
  114. Sehnoy, A., Pfannes, L., Wilhelm, F., et al. (2008). Suppression of cyclin D 1(CD1) by ON 01910.Na is associated with decreased survival or trisomy 8 myelodysplastic bone marrow: a potential targeted therapy for trisomy 8 MDS. Blood, 112. [abstract 1651]
  115. Shappell S.B., Thomas G.V., Roberts R.L., Herbert R., Ittmann M.M., Rubin M.A., Humphrey P.A., Sundberg J.P., Rozengurt N., Barrios R., the The Consensus Report from the Bar Harbor Meeting of the Mouse Models of Human Cancer Consortium Prostate Pathology Committee et al. Prostate pathology of genetically engineered mice: definitions and classification. The consensus report from the Bar Harbor meeting of the Mouse Models of Human Cancer Consortium Prostate Pathology Committee. Cancer Res. 2004;64:2270–2305. doi: 10.1158/0008-5472.can-03-0946. [DOI] [PubMed] [Google Scholar]
  116. Shen M.M., Abate-Shen C. Molecular genetics of prostate cancer: new prospects for old challenges. Genes Dev. 2010;24:1967–2000. doi: 10.1101/gad.1965810. [DOI] [PMC free article] [PubMed] [Google Scholar]
  117. Shirayama M., Zachariae W., Ciosk R., Nasmyth K. The Polo-like kinase Cdc5p and the WD-repeat protein Cdc20p/fizzy are regulators and substrates of the anaphase promoting complex in Saccharomyces cerevisiae. EMBO J. 1998;17:1336–1349. doi: 10.1093/emboj/17.5.1336. [DOI] [PMC free article] [PubMed] [Google Scholar]
  118. Smith M.R., Wilson M.L., Hamanaka R., Chase D., Kung H., Longo D.L., Ferris D.K. Malignant transformation of mammalian cells initiated by constitutive expression of the polo-like kinase. Biochem Biophys Res Commun. 1997;234:397–405. doi: 10.1006/bbrc.1997.6633. [DOI] [PubMed] [Google Scholar]
  119. Somers W.G., Saint R. A RhoGEF and Rho family GTPase-activating protein complex links the contractile ring to cortical microtubules at the onset of cytokinesis. Dev Cell. 2003;4:29–39. doi: 10.1016/s1534-5807(02)00402-1. [DOI] [PubMed] [Google Scholar]
  120. Song B., Liu X.S., Davis K., Liu X. Plk1 phosphorylation of Orc2 promotes DNA replication under conditions of stress. Mol Cell Biol. 2011;31:4844–4856. doi: 10.1128/MCB.06110-11. [DOI] [PMC free article] [PubMed] [Google Scholar]
  121. Spänkuch B., Matthess Y., Knecht R., Zimmer B., Kaufmann M., Strebhardt K. Cancer inhibition in nude mice after systemic application of U6 promoter-driven short hairpin RNAs against PLK1. J Natl Cancer Inst. 2004;96:862–872. doi: 10.1093/jnci/djh146. [DOI] [PubMed] [Google Scholar]
  122. Steegmaier M., Hoffmann M., Baum A., Lénárt P., Petronczki M., Krssák M., Gürtler U., Garin-Chesa P., Lieb S., Quant J., et al. BI 2536, a potent and selective inhibitor of polo-like kinase 1, inhibits tumor growth in vivo. Curr Biol. 2007;17:316–322. doi: 10.1016/j.cub.2006.12.037. [DOI] [PubMed] [Google Scholar]
  123. Strebhardt K. Multifaceted polo-like kinases: drug targets and antitargets for cancer therapy. Nat Rev Drug Discov. 2010;9:643–660. doi: 10.1038/nrd3184. [DOI] [PubMed] [Google Scholar]
  124. Strebhardt K., Kneisel L., Linhart C., Bernd A., Kaufmann R. Prognostic value of pololike kinase expression in melanomas. JAMA. 2000;283:479–480. doi: 10.1001/jama.283.4.479. [DOI] [PubMed] [Google Scholar]
  125. Strebhardt K., Ullrich A. Targeting polo-like kinase 1 for cancer therapy. Nat Rev Cancer. 2006;6:321–330. doi: 10.1038/nrc1841. [DOI] [PubMed] [Google Scholar]
  126. Stuermer A., Hoehn K., Faul T., Auth T., Brand N., Kneissl M., Pütter V., Grummt F. Mouse pre-replicative complex proteins colocalise and interact with the centrosome. Eur J Cell Biol. 2007;86:37–50. doi: 10.1016/j.ejcb.2006.09.002. [DOI] [PubMed] [Google Scholar]
  127. Syljuåsen R.G., Jensen S., Bartek J., Lukas J. Adaptation to the ionizing radiation-induced G2 checkpoint occurs in human cells and depends on checkpoint kinase 1 and Polo-like kinase 1 kinases. Cancer Res. 2006;66:10253–10257. doi: 10.1158/0008-5472.CAN-06-2144. [DOI] [PubMed] [Google Scholar]
  128. Takahashi T., Sano B., Nagata T., Kato H., Sugiyama Y., Kunieda K., Kimura M., Okano Y., Saji S. Polo-like kinase 1 (PLK1) is overexpressed in primary colorectal cancers. Cancer Sci. 2003;94:148–152. doi: 10.1111/j.1349-7006.2003.tb01411.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  129. Takai N., Hamanaka R., Yoshimatsu J., Miyakawa I. Polo-like kinases (Plks) and cancer. Oncogene. 2005;24:287–291. doi: 10.1038/sj.onc.1208272. [DOI] [PubMed] [Google Scholar]
  130. Takai N., Miyazaki T., Fujisawa K., Nasu K., Hamanaka R., Miyakawa I. Expression of polo-like kinase in ovarian cancer is associated with histological grade and clinical stage. Cancer Lett. 2001;164:41–49. doi: 10.1016/s0304-3835(00)00703-5. [DOI] [PubMed] [Google Scholar]
  131. Takai N., Miyazaki T., Fujisawa K., Nasu K., Hamanaka R., Miyakawa I. Polo-like kinase (PLK) expression in endometrial carcinoma. Cancer Lett. 2001;169:41–49. doi: 10.1016/s0304-3835(01)00522-5. [DOI] [PubMed] [Google Scholar]
  132. Takaki T., Trenz K., Costanzo V., Petronczki M. Polo-like kinase 1 reaches beyond mitosis—cytokinesis, DNA damage response, and development. Curr Opin Cell Biol. 2008;20:650–660. doi: 10.1016/j.ceb.2008.10.005. [DOI] [PubMed] [Google Scholar]
  133. Taylor B.S., Schultz N., Hieronymus H., Gopalan A., Xiao Y., Carver B.S., Arora V.K., Kaushik P., Cerami E., Reva B., et al. Integrative genomic profiling of human prostate cancer. Cancer Cell. 2010;18:11–22. doi: 10.1016/j.ccr.2010.05.026. [DOI] [PMC free article] [PubMed] [Google Scholar]
  134. Timms B.G. Prostate development: a historical perspective. Differentiation. 2008;76:565–577. doi: 10.1111/j.1432-0436.2008.00278.x. [DOI] [PubMed] [Google Scholar]
  135. Toczyski D.P., Galgoczy D.J., Hartwell L.H. CDC5 and CKII control adaptation to the yeast DNA damage checkpoint. Cell. 1997;90:1097–1106. doi: 10.1016/s0092-8674(00)80375-x. [DOI] [PubMed] [Google Scholar]
  136. Tokumitsu Y., Mori M., Tanaka S., Akazawa K., Nakano S., Niho Y. Prognostic significance of polo-like kinase expression in esophageal carcinoma. Int J Oncol. 1999;15:687–692. doi: 10.3892/ijo.15.4.687. [DOI] [PubMed] [Google Scholar]
  137. Toyoshima-Morimoto F., Taniguchi E., Nishida E. Plk1 promotes nuclear translocation of human Cdc25C during prophase. EMBO Rep. 2002;3:341–348. doi: 10.1093/embo-reports/kvf069. [DOI] [PMC free article] [PubMed] [Google Scholar]
  138. Toyoshima-Morimoto F., Taniguchi E., Shinya N., Iwamatsu A., Nishida E. Polo-like kinase 1 phosphorylates cyclin B1 and targets it to the nucleus during prophase. Nature. 2001;410:215–220. doi: 10.1038/35065617. [DOI] [PubMed] [Google Scholar]
  139. Tsvetkov L., Stern D.F. Interaction of chromatin-associated Plk1 and Mcm7. J Biol Chem. 2005;280:11943–11947. doi: 10.1074/jbc.M413514200. [DOI] [PubMed] [Google Scholar]
  140. van de Weerdt B.C., Medema R.H. Polo-like kinases: a team in control of the division. Cell Cycle. 2006;5:853–864. doi: 10.4161/cc.5.8.2692. [DOI] [PubMed] [Google Scholar]
  141. van Leenders G.J.L.H., Schalken J.A. Epithelial cell differentiation in the human prostate epithelium: implications for the pathogenesis and therapy of prostate cancer. Crit Rev Oncol Hematol. 2003;46:S3–S10. doi: 10.1016/s1040-8428(03)00059-3. [DOI] [PubMed] [Google Scholar]
  142. van Vugt M.A.T.M., Gardino A.K., Linding R., Ostheimer G.J., Reinhardt H.C., Ong S.-E., Tan C.S., Miao H., Keezer S.M., Li J., et al. A mitotic phosphorylation feedback network connects Cdk1, Plk1, 53BP1, and Chk2 to inactivate the G(2)/M DNA damage checkpoint. PLoS Biol. 2010;8:e1000287. doi: 10.1371/journal.pbio.1000287. [DOI] [PMC free article] [PubMed] [Google Scholar]
  143. von Hoff D.D., Taylor C., Rubin S., et al. A phase I and pharmacokinetic study of HMN-214, a novel oral Polo-like kinase inhibitor, in patients with advanced solid tumors. [abstract] J Clin Oncol. 2004;22:3034. [Google Scholar]
  144. Vose, J., Young, A., Friedberg, J.W., et al. (2008). Phase I dose-escalation trial of BI 2536, a polo-like kinase 1 inhibitor, in relapsed and refractory Non-Hodgkin’s lymphoma. Blood 112. [abstract 233]
  145. Wäsch R., Engelbert D. Anaphase-promoting complex-dependent proteolysis of cell cycle regulators and genomic instability of cancer cells. Oncogene. 2005;24:1–10. doi: 10.1038/sj.onc.1208017. [DOI] [PubMed] [Google Scholar]
  146. Watanabe N., Arai H., Nishihara Y., Taniguchi M., Watanabe N., Hunter T., Osada H. M-phase kinases induce phospho-dependent ubiquitination of somatic Wee1 by SCFbeta-TrCP. Proc Natl Acad Sci U S A. 2004;101:4419–4424. doi: 10.1073/pnas.0307700101. [DOI] [PMC free article] [PubMed] [Google Scholar]
  147. Watanabe N., Sekine T., Takagi M., Iwasaki J., Imamoto N., Kawasaki H., Osada H. Deficiency in chromosome congression by the inhibition of Plk1 polo box domain-dependent recognition. J Biol Chem. 2009;284:2344–2353. doi: 10.1074/jbc.M805308200. [DOI] [PubMed] [Google Scholar]
  148. Weichert W., Denkert C., Schmidt M., Gekeler V., Wolf G., Köbel M., Dietel M., Hauptmann S. Polo-like kinase isoform expression is a prognostic factor in ovarian carcinoma. Br J Cancer. 2004;90:815–821. doi: 10.1038/sj.bjc.6601610. [DOI] [PMC free article] [PubMed] [Google Scholar]
  149. Weichert W., Schmidt M., Gekeler V., Denkert C., Stephan C., Jung K., Loening S., Dietel M., Kristiansen G. Polo-like kinase 1 is overexpressed in prostate cancer and linked to higher tumor grades. Prostate. 2004;60:240–245. doi: 10.1002/pros.20050. [DOI] [PubMed] [Google Scholar]
  150. Wolf G., Elez R., Doermer A., Holtrich U., Ackermann H., Stutte H.J., Altmannsberger H.M., Rübsamen-Waigmann H., Strebhardt K. Prognostic significance of polo-like kinase (PLK) expression in non-small cell lung cancer. Oncogene. 1997;14:543–549. doi: 10.1038/sj.onc.1200862. [DOI] [PubMed] [Google Scholar]
  151. Wolf G., Hildenbrand R., Schwar C., Grobholz R., Kaufmann M., Stutte H.J., Strebhardt K., Bleyl U. Polo-like kinase: a novel marker of proliferation: correlation with estrogen-receptor expression in human breast cancer. Pathol Res Pract. 2000;196:753–759. doi: 10.1016/S0344-0338(00)80107-7. [DOI] [PubMed] [Google Scholar]
  152. Wolfe B.A., Takaki T., Petronczki M., Glotzer M. Polo-like kinase 1 directs assembly of the HsCyk-4 RhoGAP/Ect2 RhoGEF complex to initiate cleavage furrow formation. PLoS Biol. 2009;7:e1000110. doi: 10.1371/journal.pbio.1000110. [DOI] [PMC free article] [PubMed] [Google Scholar]
  153. Wong O.K., Fang G. Plx1 is the 3F3/2 kinase responsible for targeting spindle checkpoint proteins to kinetochores. J Cell Biol. 2005;170:709–719. doi: 10.1083/jcb.200502163. [DOI] [PMC free article] [PubMed] [Google Scholar]
  154. Wu Z.Q., Liu X. Role for Plk1 phosphorylation of Hbo1 in regulation of replication licensing. Proc Natl Acad Sci U S A. 2008;105:1919–1924. doi: 10.1073/pnas.0712063105. [DOI] [PMC free article] [PubMed] [Google Scholar]
  155. Wu Z.Q., Yang X., Weber G., Liu X. Plk1 phosphorylation of TRF1 is essential for its binding to telomeres. J Biol Chem. 2008;283:25503–25513. doi: 10.1074/jbc.M803304200. [DOI] [PMC free article] [PubMed] [Google Scholar]
  156. Yang X., Li H., Liu X.S., Deng A., Liu X. Cdc2-mediated phosphorylation of CLIP-170 is essential for its inhibition of centrosome reduplication. J Biol Chem. 2009;284:28775–28782. doi: 10.1074/jbc.M109.017681. [DOI] [PMC free article] [PubMed] [Google Scholar]
  157. Yang X., Li H., Zhou Z., Wang W.H., Deng A., Andrisani O., Liu X. Plk1-mediated phosphorylation of Topors regulates p53 stability. J Biol Chem. 2009;284:18588–18592. doi: 10.1074/jbc.C109.001560. [DOI] [PMC free article] [PubMed] [Google Scholar]
  158. Yim H., Erikson R.L. Polo-like kinase 1 depletion induces DNA damage in early S prior to caspase activation. Mol Cell Biol. 2009;29:2609–2621. doi: 10.1128/MCB.01277-08. [DOI] [PMC free article] [PubMed] [Google Scholar]
  159. Yoo H.Y., Kumagai A., Shevchenko A., Shevchenko A., Dunphy W.G. Adaptation of a DNA replication checkpoint response depends upon inactivation of Claspin by the Polo-like kinase. Cell. 2004;117:575–588. doi: 10.1016/s0092-8674(04)00417-9. [DOI] [PubMed] [Google Scholar]
  160. Yuan J., Eckerdt F., Bereiter-Hahn J., Kurunci-Csacsko E., Kaufmann M., Strebhardt K. Cooperative phosphorylation including the activity of polo-like kinase 1 regulates the subcellular localization of cyclin B1. Oncogene. 2002;21:8282–8292. doi: 10.1038/sj.onc.1206011. [DOI] [PubMed] [Google Scholar]
  161. Yüce O., Piekny A., Glotzer M. An ECT2-centralspindlin complex regulates the localization and function of RhoA. J Cell Biol. 2005;170:571–582. doi: 10.1083/jcb.200501097. [DOI] [PMC free article] [PubMed] [Google Scholar]
  162. Zhao W.M., Fang G. MgcRacGAP controls the assembly of the contractile ring and the initiation of cytokinesis. Proc Natl Acad Sci U S A. 2005;102:13158–13163. doi: 10.1073/pnas.0504145102. [DOI] [PMC free article] [PubMed] [Google Scholar]
  163. Zhou T., Aumais J.P., Liu X., Yu-Lee L.-Y., Erikson R.L. A role for Plk1 phosphorylation of NudC in cytokinesis. Dev Cell. 2003;5:127–138. doi: 10.1016/s1534-5807(03)00186-2. [DOI] [PubMed] [Google Scholar]

Articles from Protein & Cell are provided here courtesy of Oxford University Press

RESOURCES